"Isocitrate Dehydrogenase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An enzyme of the oxidoreductase class that catalyzes the conversion of isocitrate and NAD+ to yield 2-ketoglutarate, carbon dioxide, and NADH. It occurs in cell mitochondria. The enzyme requires Mg2+, Mn2+; it is activated by ADP, citrate, and Ca2+, and inhibited by NADH, NADPH, and ATP. The reaction is the key rate-limiting step of the citric acid (tricarboxylic) cycle. (From Dorland, 27th ed) (The NADP+ enzyme is EC 1.1.1.42.) EC 1.1.1.41.
| Descriptor ID |
D007521
|
| MeSH Number(s) |
D08.811.682.047.820.475
|
| Concept/Terms |
Isocitrate Dehydrogenase- Isocitrate Dehydrogenase
- Dehydrogenase, Isocitrate
- NAD Isocitrate Dehydrogenase
- Dehydrogenase, NAD Isocitrate
- Isocitrate Dehydrogenase, NAD
- Isocitrate Dehydrogenase (NAD+)
|
Below are MeSH descriptors whose meaning is more general than "Isocitrate Dehydrogenase".
Below are MeSH descriptors whose meaning is more specific than "Isocitrate Dehydrogenase".
This graph shows the total number of publications written about "Isocitrate Dehydrogenase" by people in this website by year, and whether "Isocitrate Dehydrogenase" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 1 | 2 |
| 2015 | 2 | 1 | 3 |
| 2016 | 1 | 0 | 1 |
| 2017 | 0 | 1 | 1 |
| 2018 | 2 | 1 | 3 |
| 2019 | 1 | 1 | 2 |
| 2020 | 1 | 1 | 2 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Isocitrate Dehydrogenase" by people in Profiles.
-
Anaplastic ganglioglioma-A diagnosis comprising several distinct tumour types. Neuropathol Appl Neurobiol. 2022 12; 48(7):e12847.
-
Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma: A Randomized Clinical Trial. JAMA Oncol. 2020 12 01; 6(12):1939-1946.
-
Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma. J Clin Oncol. 2020 10 10; 38(29):3407-3417.
-
Polysomy is associated with poor outcome in 1p/19q codeleted oligodendroglial tumors. Neuro Oncol. 2019 09 06; 21(9):1164-1174.
-
Prognostic significance of O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation and isocitrate dehydrogenase-1 (IDH-1) mutation in glioblastoma multiforme patients: A single-center experience in the Middle East region. Clin Neurol Neurosurg. 2019 07; 182:92-97.
-
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML. N Engl J Med. 2018 Jun 21; 378(25):2386-2398.
-
DNA methylation-based reclassification of olfactory neuroblastoma. Acta Neuropathol. 2018 08; 136(2):255-271.
-
Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations. Acta Neuropathol. 2018 08; 136(2):273-291.
-
Sirtuin 3 Deregulation Promotes Pulmonary Fibrosis. J Gerontol A Biol Sci Med Sci. 2017 May 01; 72(5):595-602.
-
Impact of IDH1 mutation status on outcome in clinical trials for recurrent glioblastoma. J Neurooncol. 2016 08; 129(1):147-54.